The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | IFM2021-01 trial Cohort A: teclistamab + daratumumab in older patients with newly diagnosed myeloma
Salomon Manier, MD, PhD, Lille Hospital University, Lille, France, presents the results of Cohort A of the IFM2021-01 trial (EU CT 2024-514101-65; NCT05572229) evaluating the combination of teclistamab and daratumumab in older patients with newly diagnosed multiple myeloma (MM) who are ineligible for high-dose chemotherapy with autologous stem cell transplantation (autoSCT). Dr Manier highlights that all patients responded to the treatment, with most achieving complete response (CR) and all evaluable patients achieving measurable residual disease (MRD) negativity at 6 months. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
